• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Surges Over 100 Points; US Services PMI Rises In February

    3/3/23 10:15:24 AM ET
    $BFRG
    $BMRA
    $COMP
    $CYTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $BFRG alert in real time by email

    U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday.

    Following the market opening Friday, the Dow traded up 0.42% to 33,140.85 while the NASDAQ rose 1.02% to 11,579.87. The S&P 500 also rose, gaining, 0.72% to 4,010.13.

    Check This Out: Top 5 Real Estate Stocks That Are Set To Fly In Marchh

     

    Leading and Lagging Sectors

    • Real estate shares rose 1.4% on Friday. Meanwhile, top gainers in the sector included Compass, Inc (NYSE:COMP), up 12%, and WeWork Inc. (NYSE:WE), up 6%.
    • In trading on Friday, consumer staples shares fell by 0.6%.

     

    Top Headline

    The S&P Global Services PMI rose to 50.6 in February from a preliminary reading of 50.5 and compared to January's level of 46.8.

     

    Equities Trading UP

    • Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares shot up 76% to $4.13 after the company said data from a recent peer-reviewed clinical study demonstrated Bentrio's superior nasal residence time and rheological properties.
    • Shares of Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) got a boost, shooting 19% to $3.24. Bullfrog AI recently priced its IPO at $6.50 per share.
    • HPX Corp. (NYSE:HPX) shares were also up, gaining 43% to $24.78. The company’s shareholders recently approved the proposed business combination with Emergencia Participacoes.

     

    Equities Trading DOWN

    • Praxis Precision Medicines, Inc. (NASDAQ:PRAX) shares tumbled 62% to $1.10 after the company announced topline results from the Essential1 study evaluating the efficacy, safety, and tolerability of ulixacaltamide (PRAX-944) for essential tremor (ET).
    • Shares of Veru Inc. (NASDAQ:VERU) were down 38% to $2.3350 after the FDA declined to grant the company's request for Emergency Use Authorization for sabizabulin.
    • Biomerica, Inc. (NASDAQ:BMRA) was down, falling 18% to $2.2695. Biomerica raised $8 million via secondary stock offering at $2.40 per share for general corporate purposes.

    Also Check This Out: Bitcoin Falls Below This Key Level; Conflux Becomes Top Loser

     

    Commodities

    In commodity news, oil traded down 0.8% to $77.51 while gold traded up 0.5% at $1,849.10.

    Silver traded up 0.3% to $20.97 on Friday while copper rose 0.5% to $4.0955.

     

    Euro zone

    European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.8%, London’s FTSE 100 slipped 0.01% while Spain’s IBEX 35 Index rose 1.2%. The German DAX gained 1.5% French CAC 40 rose 0.9% and Italy’s FTSE MIB Index gained 1.5%.

    The S&P Global Eurozone services PMI fell to 52.7 in February versus a preliminary reading of 53.0. German services PMI was revised lower to 50.9 in February compared to a preliminary estimate of 51.3, while French services PMI was revised higher to 53.1 in February from a flash reading of 52.8.

    Italy’s GDP shrank by 0.1% quarter-over-quarter during the three months leading to December. The S&P Global Italy services PMI increased to 51.6 in February versus 51.2 a month ago. Spain services PMI climbed to 56.7 in February versus 52.7 in the prior month.

     

    Asia Pacific Markets

    Asian markets closed higher on Friday, with Japan’s Nikkei 225 gaining 1.56%, Hong Kong’s Hang Seng Index rising 0.68% and China’s Shanghai Composite Index gaining 0.54%. India’s S&P BSE Sensex climbed 1.8%.

    The S&P Global Indian services PMI climbed to a 12-year high level of 59.4 in February, while Caixin China general services PMI rose to 55.0 in February from 52.9 in the prior month. The S&P Global Hong Kong PMI climbed to 53.9 in February versus 51.2 in January, while Japanese services PMI was revised higher to 54.0 during February.

     

    Economics

    • The S&P Global Services PMI rose to 50.6 in February from a preliminary reading of 50.5 and compared to January's level of 46.8.
    • The S&P Global Composite PMI slipped to 50.1 in February versus from a preliminary reading of 50.2.

    Now Read This: https://www.benzinga.com/news/23/03/31192039/insiders-selling-sunrun-applied-materials-and-2-other-stocks

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 105,384,010 cases with around 1,146,630 deaths. India confirmed a total of at least 44,687,160 cases and 530,770 deaths, while France reported over 39,630,950 COVID-19 cases with 165,000 deaths. In total, there were at least 680,386,210 cases of COVID-19 worldwide with more than 6,803,050 deaths.

    Get the next $BFRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRG
    $BMRA
    $COMP
    $CYTO

    CompanyDatePrice TargetRatingAnalyst
    Praxis Precision Medicines Inc.
    $PRAX
    2/2/2026$282.00Equal Weight
    Wells Fargo
    Compass Inc.
    $COMP
    1/27/2026$14.00Neutral
    Goldman
    Compass Inc.
    $COMP
    1/26/2026$15.00Overweight
    Analyst
    Compass Inc.
    $COMP
    1/20/2026Hold → Buy
    Deutsche Bank
    Veru Inc.
    $VERU
    12/18/2025$25.00Buy
    Canaccord Genuity
    Praxis Precision Medicines Inc.
    $PRAX
    12/15/2025$250.00 → $750.00Outperform
    Oppenheimer
    Compass Inc.
    $COMP
    12/8/2025$13.00Equal Weight → Overweight
    Barclays
    Compass Inc.
    $COMP
    11/19/2025Buy
    Odeon
    More analyst ratings

    $BFRG
    $BMRA
    $COMP
    $CYTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rankowitz Michael L bought $84,351 worth of shares (150,000 units at $0.56), increasing direct ownership by 150% to 250,000 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    2/20/25 10:00:11 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fisch Harry bought $5,000 worth of shares (4,000 units at $1.25), increasing direct ownership by 0.52% to 774,736 units (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    5/28/24 5:04:02 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barnette K Gary bought $6,696 worth of shares (5,000 units at $1.34) (SEC Form 4)

    4 - VERU INC. (0000863894) (Issuer)

    5/24/24 6:57:00 PM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $BMRA
    $COMP
    $CYTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

    -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update. "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for

    2/11/26 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass, Inc. to Announce Fourth Quarter and Full-Year 2025 Results on February 26

    NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Compass, Inc., d/b/a Compass International Holdings (the "Company") (NYSE:COMP), a global real estate services company, announces its fourth quarter and full-year 2025 financial results will be released after market close on Thursday, February 26, 2026. The Company will host a conference call to discuss its results at 5:00 p.m. ET / 2:00 p.m. PT that afternoon. Call details are as follows: The conference call and shareholder presentation will be accessible online via the Company's Investor Relations website, https://investors.compass.com.

    2/9/26 4:11:00 PM ET
    $COMP
    EDP Services
    Technology

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $BMRA
    $COMP
    $CYTO
    SEC Filings

    View All

    SEC Form 10-Q filed by Veru Inc.

    10-Q - VERU INC. (0000863894) (Filer)

    2/11/26 10:32:14 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Veru Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - VERU INC. (0000863894) (Filer)

    2/11/26 7:00:14 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Praxis Precision Medicines Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - Praxis Precision Medicines, Inc. (0001689548) (Filer)

    2/10/26 4:52:49 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $BMRA
    $COMP
    $CYTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BFRG
    $BMRA
    $COMP
    $CYTO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    Director Arbuckle Stuart A was granted 1,166 shares (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    2/10/26 4:59:33 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kindler Jeffrey B was granted 1,166 shares (SEC Form 4)

    4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)

    2/10/26 4:57:40 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and CEO Reffkin Robert L. converted options into 1,154,593 shares and covered exercise/tax liability with 638,797 shares (SEC Form 4)

    4 - Compass, Inc. (0001563190) (Issuer)

    2/6/26 4:30:30 PM ET
    $COMP
    EDP Services
    Technology

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $BMRA
    $COMP
    $CYTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Praxis Precision Medicines with a new price target

    Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00

    2/2/26 6:51:57 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Compass with a new price target

    Goldman resumed coverage of Compass with a rating of Neutral and set a new price target of $14.00

    1/27/26 8:45:14 AM ET
    $COMP
    EDP Services
    Technology

    Analyst initiated coverage on Compass with a new price target

    Analyst initiated coverage of Compass with a rating of Overweight and set a new price target of $15.00

    1/26/26 10:01:23 AM ET
    $COMP
    EDP Services
    Technology

    $BFRG
    $BMRA
    $COMP
    $CYTO
    Leadership Updates

    Live Leadership Updates

    View All

    Coldwell Banker Real Estate Announces 2025 Year-End Award Winners

    The brand recognizes the top affiliated sales professionals, teams, offices and companies who have demonstrated exceptional performance across multiple sales categories in the past year MADISON, N.J., Jan. 29, 2026 /PRNewswire/ -- Coldwell Banker Real Estate LLC today announced the 2025 recipients of its annual year-end awards, recognizing top‑ranking performers whose achievements exemplify the highest standards of excellence across the Coldwell Banker® network. "Each year, the dedication of the Coldwell Banker real estate professionals, teams, and offices elevates the standar

    1/29/26 10:00:00 AM ET
    $COMP
    EDP Services
    Technology

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. "These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage developm

    1/8/26 4:45:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $BMRA
    $COMP
    $CYTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 7:53:30 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:50:15 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:46:12 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BFRG
    $BMRA
    $COMP
    $CYTO
    Financials

    Live finance-specific insights

    View All

    Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

    -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update. "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for

    2/11/26 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass, Inc. to Announce Fourth Quarter and Full-Year 2025 Results on February 26

    NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Compass, Inc., d/b/a Compass International Holdings (the "Company") (NYSE:COMP), a global real estate services company, announces its fourth quarter and full-year 2025 financial results will be released after market close on Thursday, February 26, 2026. The Company will host a conference call to discuss its results at 5:00 p.m. ET / 2:00 p.m. PT that afternoon. Call details are as follows: The conference call and shareholder presentation will be accessible online via the Company's Investor Relations website, https://investors.compass.com.

    2/9/26 4:11:00 PM ET
    $COMP
    EDP Services
    Technology

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care